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Abstract
MicroRNAs are endogenous posttranscriptional modulators that negatively control the expression of their target
genes and play an important role in the development and progression of many malignancies, including colorectal
carcinoma. In particular, expression of microRNA-21 (miR-21) is greatly increased in chemotherapy-resistant (CR)
colon cancer cells that are enriched in undifferentiated cancer stem/stem-like cells (CSCs/CSLCs). We hypothesize
that miR-21 plays a critical role in regulating differentiation of CR colon cancer cells. Indeed, we observed that down-
regulation of miR-21 in CR colon cancer cells (HCT-116 or HT-29) by antisense miR-21 induced differentiation, as
evidenced by marked increases in cytokeratin-20 (CK-20) expression and alkaline phosphatase activity. These
changes were accompanied by a significant reduction in the expression of colon CSC/CSLC marker CD44, colono-
sphere formation, and T-cell factor/lymphoid enhancer factor (TCF/LEF) activity but increased the expression of pro-
apoptotic programmed cell death 4 gene. Induction of differentiation greatly increased sensitivity of CR colon cancer
cells to the growth inhibitory properties of all three regimens tested: 5-fluorouracil + oxaliplatin (FUOX), difluorinated
curcumin (CDF), and the combination of CDF and FUOX. However, themagnitude of inhibition of growth by either CDF
(75%) alone or CDF + FUOX (80%) was much higher than that observed with only FUOX (40%). Growth inhibition by
CDF and CDF + FUOX in differentiating CR colon cancer cells was associated with a 98% to 99% reduction in the
expression of CD44 and epidermal growth factor receptor (EGFR). However, down-regulation of CK-20 in CR colon
cancer cells produced no significant change in cellular growth in the absence or presence of FUOX, when compared
with the corresponding controls. The current observation suggests that CDF and CDF + FUOX are highly effective
in inhibiting growth and reducing colon CSCs/CSLCs in anti–miR-21–induced differentiating CR colon cancer cells
and supports our contention that differentiation enhances susceptibility of CR cancer cells to conventional and non-
conventional therapeutic regimen.
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Introduction
Colorectal cancer is one of the most common cancers and the second
leading cause of cancer-related deaths in the United States with about
140,000 newly diagnosed cases per year. Although current treatments
involving a combination of surgical resection, radiation, and chemo-
therapy have increased the patient’s five-year survival, nearly 50%
of patients with colorectal carcinoma show recurrence of the disease
with about 50,000 deaths per year [1]. Therefore, an improved
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therapeutic strategy specifically targeting the recurrent disease is
desperately needed.
Carcinoma recurrence in part is due to the fact that conventional
chemotherapy only targets the rapidly dividing cells that form bulk
of the tumor. While chemotherapy can shrink the size of the tumor,
the tumor initiating or cancer stem/stem-like cells (CSCs/CSLCs)
that are resistant to chemotherapy are thought to be the leading cause
of cancer recurrence [2]. Moreover, continued use of conventional
chemotherapeutics is associated with added toxicities, some of which
are even fatal.
CSCs/CSLCs are defined as self-renewing population of undifferen-
tiated cells within a tumor that are primarily responsible for populat-
ing the bulk of the tumor. They have been shown to be resistant to
radiation and chemotherapy and are thought to be responsible for
tumor initiation, progression, metastasis, and relapse [3]. CSCs/CSLCs
isolated from different solid tumors, including the colon, are usually
identified by specific surface epitopes. Colon CSCs/CSLCs have been
shown to express CD44, CD166, CD133, and epithelial-specific
antigen surface markers [4]. We have observed that in humans, colon
CSCs/CSLCs are present not only in premalignant adenomas but also
in normal appearing colonic mucosa and that the population of CSCs/
CSLCs increases with advancing age, suggesting that they may be partly
responsible for the age-related rise in colorectal cancer [5].
Like normal stem cells, CSCs/CSLCs grow slowly and are more
likely to survive chemotherapy than other cells [6]. Hence, the pro-
portion of CSCs/CSLCs in the tumor increases after conventional
chemotherapy. We have recently reported that exposure of colon can-
cer HCT-116 or HT-29 cells to the combination of 5-fluorouracil
(5-FU) and oxaliplatin (Ox), the backbone of colorectal cancer con-
ventional chemotherapy, inhibited their growth and led to enrichment
of CSC/CSLC phenotype where Wnt/β-catenin signaling played a
critical role in regulating their growth and maintenance [7,8]. More
interestingly, the levels of microRNA-21 (miR-21), an oncomiR, were
found to be greatly increased in CSCs/CSLCs-enriched chemotherapy-
resistant (CR) colon cancer HCT-116 and HT-29 cells, indicating that
miR-21 may play a role in regulating the growth of CSCs/CSLCs [9].
MicroRNAs (miRNAs) comprise a broad class of small (19–22
nucleotide) endogenous RNAs that negatively control the expression
of the target genes by cleaving mRNA or through translation repres-
sion [10]. It is estimated that miRNAs can control the expression of
approximately 30% of all proteins in humans and regulate various cel-
lular processes. Many miRNAs are found to be aberrantly expressed
in several pathologic conditions, including cancer, leading to the iden-
tification of “miRNA signature” characteristics of certain tumors [11].
Tumor-specific miRNA expression profiles are also functionally rele-
vant because many miRNAs act as tumor suppressors or as oncogenes
(oncomiRs) [12].
miR-21 has been found to be overexpressed in most epithelial
cancers including colorectal cancers. Knockdown of miR-21 in cancer
cells impairs growth, induces apoptosis, and reduces migration and
invasion of cancer cells [13]. Forced expression of miR-21 leads to
increased T-cell factor/lymphoid enhancer factor (TCF/LEF) activity,
augmentation of the expression of c-Myc and cyclin D accompanied
by increased sphere forming ability in vitro, and tumor formation in
severe combined immunodeficiency (SCID) mice [9].
The target genes of miR-21 were determined to be tumor-suppressive
genes such as PTEN, programmed cell death 4 gene (PDCD4 ), and trans-
forming growth factor βR2 [14]. miR-21 is believed to play a pivotal role
in the progression of many malignancies. Therefore, it is not surpris-
ing that miR-21 is involved in diverse biologic processes, including cell
differentiation, proliferation, and apoptosis, presumably by modulating
target proteins [15]. The primary objective of the current investigation
was to examine whether down-regulation of miR-21 in CSC/CSLC-
enriched CR colon cancer cells would induce differentiation. Herein,
we report that down-regulation of miR-21 by anti–miR-21 in CR
colon cancer cells induces differentiation and increases their suscep-
tibility to conventional or/and nonconventional therapeutic regimens.
Materials and Methods
Cell Lines and Generation of CR Cells
Human colon cancer HCT-116 and HT-29 cells were obtained
from the American Type Culture Collection (ATCC, Rockville,
MD). They were maintained in Dulbecco’s modified Eagle’s medium
(4.5 g/l D-glucose) supplemented with 10% FBS (Invitrogen, Grand
Island, NY) and 1% antibiotic/antimycotic in tissue culture flasks in
a humidified incubator at 37°C in an atmosphere of 95% air and
5% carbon dioxide. The medium was changed two times a week,
and cells were passaged using 0.05% trypsin/EDTA (Invitrogen).
FOLFOX/FUOX (5-FU + Oxaliplatin)–resistant (CR) cell lines
were generated in our laboratory as described previously [8,16], Briefly,
HCT-116 or HT-29 cells were incubated with a clinically relevant
dose of FUOX (25 μM 5-FU and 0.625 μM oxaliplatin) for 72 hours.
The medium was removed and the adherent cells, which survived the
FUOX insult, were cultured in Dulbecco’s modified Eagle’s medium
containing 10% FBS without the drugs for 3 to 4 days. The add-
remove FUOX cycle was repeated 12 times. The surviving cells were
then passaged and exposed to higher doses of combination of 5-FU
and Ox (100 μM 5-FU + 2.5 μM oxaliplatin) for approximately 2
to 3 weeks. Finally, the CR cells were maintained in normal culture
medium containing FUOX (50 μM 5-FU + 1.25 μM oxaliplatin).
The medium was changed two times a week and the cells were passaged
using trypsin/EDTA.
Anti–miR-21 and Cytokeratin-20 siRNA Transfection
For transfection of siRNA into the parental and CR colon cells,
Oligofectamine reagent (Invitrogen Corp, Carlsbad, CA) and serum-
free Opti-MEM (Invitrogen Corp) medium was used to prepare trans-
fection complexes according to the manufacturer’s instructions. Briefly,
single-cell suspension was plated onto six-well tissue culture plates with
normal growth medium overnight to achieve 25% to 30% confluence.
Next day, the medium was removed, washed twice with serum-free
Opti-MEM (Invitrogen Corp) medium before adding the complexes
containing nontargeted, anti–miR-21 or cytokeratin-20 (CK-20) siRNA
(Integrated DNA Technologies Inc, Coralville, IA). After 2 days of
transfection, the cells were collected and analyzed for mRNA, protein
expression, or cellular growth assay.
Determination of Cellular Growth
The growth of CR colon cancer HCT-116 cells in response to FUOX
(100 μM 5-FU + 2.5 μM oxaliplatin), difluorinated curcumin (CDF;
2.0 μM) and FUOX + CDF was assessed by 3-(4,5-dimethylthiazol-
2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay as described
previously [17].
Western Blot Analysis
Western blot analysis was performed essentially according to
our standard protocol [18,19]. Briefly, the cells were solubilized in
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lysis buffer and the protein concentration was determined by the
Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA). After electro-
phoresis, proteins were transferred electrophoretically onto the
supported polyvinylidene difluoride membrane (Millipore Corp,
Bedford, MA) and incubated for 1 hour at room temperature with
blocking buffer, TBS-T [20 mM Tris (pH 7.6), 100 μM NaCl, 0.1%
Tween-20], and 5% nonfat dry milk with gentle agitation. After wash-
ing the membranes with TBS-T, they were incubated overnight with
primary antibodies in TBS-T buffer containing 5% milk at 4°C. The
membranes were washed with TBS-T, subsequently incubated with
appropriate secondary antibodies in TBS-T/5% milk for 1 to 2 hours
at room temperature. The membranes were washed again with TBS-T,
and the protein bands were visualized by enhanced chemiluminescence
detection system (Amersham, Piscataway, NJ). The membranes were
stripped (2× for 15 minutes at 55°C) in stripping buffer contain-
ing 100 mM 2-mercaptoethanol, 2% sodium dodecyl sulfate, and
62.5 mM Tris-HCl (pH 6.7) and reprobed for β-actin. All Western
blots were performed at least three times for each experiment.
Isolation of RNA and Quantitative Polymerase Chain
Reaction Analysis
Total RNA was extracted from different cells using RNA-STAT
solution (Tel Test, Friendswood, TX) according to the manufacturer’s
instruction. The total RNA was treated with DNase I and purified with
phenol-chloroform. RNA concentration was measured spectrophoto-
metrically at an OD of 260 nm.
Quantitative reverse transcription–polymerase chain reaction (qRT-
PCR) was performed using the GeneAmp RNA PCR Kit (Applied
Biosystems, Foster City, CA). Five microliters of cDNA products were
amplified with SYBR Green Quantitative PCR Master Mix (Applied
Biosystems). PCR primers were used as follows: pri-miR-21, forward:
5′-tgagactgatgttgactgttgaa-3′ and reverse: 5′-tgtcagacagcccatcgac-3′;
CK-20, forward: 5′-tgaagagctgcgaagtcaga-3′ and reverse: 5′-gaagtcctca-
gcagccagtt-3′; CD44, forward: 5′-aaggtggagcaaacacaacc-3′, reverse:
5′-actgcaatgcaaactgcaag-3′; epidermal growth factor receptor (EGFR),
forward: 5′-cagcgctaccttgtcattca-3′, reverse: 5′-cgtcgtccatgtcttcttca-3′;
β-actin, forward: 5′-cccagcacaatgaagatcaa-3′ and reverse 5′-acatctgctg-
gaaggtggac-3′. Reactions were carried out in Applied Biosystems
7500 Real-Time PCR System; the conditions for PCR running were
given as follows: for activating the DNA polymerase, hot start was per-
formed for 10 minutes at 95°C and then cycling at 95°C for 15 seconds
and 60°C for 1 minute for a total of 40 cycles.
Quantitation of miR-21
TaqMan microRNA assays were used to quantitate miR-21 in
different colon cancer cells according to the manufacturer’s instruction
(Applied Biosystems). Briefly, cDNA synthesis was carried out with the
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems).
The miRNA RT-PCR primers for miR-21 and endogenous control
RNU6B were purchased from Applied Biosystems. Real-time qRT-
PCR analysis was carried out using Applied Biosystems 7500 Real-
Time PCR System. The PCR mix containing TaqMan 2× Universal
PCR Master Mix were processed as follows: 95°C for 10 minutes
and then 95°C for 15 seconds and 60°C for 60 seconds for up to
40 cycles. Signal was collected at the endpoint of every cycle. The gene
expression ΔCT values of miRNAs from each sample were calculated
by normalizing with internal control RNU6B, and relative quantitation
values were plotted.
TCF/LEF Dual-Luciferase Assay
The activation of transcription factor TCF/LEF was evaluated by
using Cignal TCF/LEF Reporter Assay Kit (SA Biosciences, Frederick,
MD) as described previously [20]. Briefly, the cells were grown to
25% to 30% confluence and co-transfected with TCF/LEF reporter
constructs along with either nontargeted (control), anti–miR-21, or
β-catenin siRNAs (Integrated DNA Technologies Inc) using SureFECT
transfection reagent (SA Biosciences) according to the manufacturer’s
instructions. After transfection, the TCF/LEF activity reporter assays
were performed 48 hours post-transfection using a Dual-Luciferase
Assay Kit (Promega Biosciences, San Luis Obispo, CA) following the
instructions outlined by the manufacturer.
Statistical Analysis
Unless otherwise stated, data are expressed as means ± SEM.
Where applicable, the results were analyzed using analysis of variance
followed by Fisher protected least significant difference or Scheffé
test. P < .05 was designated as the level of significance.
Results
Down-regulation of miR-21 Induces Differentiation of CR
Colon Cancer Cells
miR-21 has been recently referred to as an “oncomiR” (an miRNA
with oncogenic properties) [21]. This miRNA, which is normally
Figure 1. Down-regulation of miR-21 in CR colon cancer HCT-116
cells through transfection of anti–miR-21 (A) lowers the levels of
both pri-miR-21 and mature miR-21, (B) decreases the expression
of CD44 and EGFR, and (C) stimulates the expression of PDCD4
but reduces CD44. In this and all subsequent studies, the control
cells were transfected with scrambled miRNAs. The data represent
means ± SD of three independent experiments.
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upregulated in many solid tumors including colon tumors [22],
promotes cell transformation by targeting the PDCD4 [13] through
posttranscriptional down-regulation [22]. We have reported that CR
colon cancer HCT-116 and HT-29 cells exhibit enrichment of CSCs/
CSLCs and elevated levels of mature miR-21 and that miR-21 in-
duces stemness in colon cancer cells [9]. These properties of miR-21
prompted us to examine whether down-regulation of miR-21 in CR
colon cancer cells would induce differentiation of CSCs.
Down-regulation of miR-21 through transfection of anti–miR-21 in
CR HCT-116 cells caused about 40% reduction in pri-miR-21 and
mature miR-21 levels (Figure 1A) and elevated the levels of PDCD4
(Figure 1C), one of the targets of miR-21, and produced approximately
50% reduction in the expression of EGFR and CD44 (Figure 1B), the
latter being one of the markers of colon CSCs/CSLCs. Additionally,
down-regulation of miR-21 in CR HCT-116 cells was found to lower
the ability of these cells to form colonospheres (Figure 2, A and B), one
of the primary properties of colon CSCs/CSLCs. These changes were
associated with marked increases in both mRNA and protein expres-
sion of CK-20 [23] and a 50% increase in alkaline phosphatase activity
(Figure 2, C and D), indicating induction of differentiation of CR
HCT-116 cells following down-regulation of miR-21.
Wnt/β-Catenin Signaling Pathway Plays a Role in Regulating
miR-21–Mediated Differentiation of CR Colon Cancer Cells
The next set of experiments was undertaken to examine the potential
mechanisms of miR-21–mediated differentiation in CR colon cancer
cells. The Wnt/β-catenin signaling pathway that regulates β-catenin/
TCF–driven gene transcription is known to be activated in many malig-
nancies, including colorectal cancer [24]. This signaling pathway also
plays a critical role in regulating proliferation of colon CSCs/CSLCs
[20]. We have reported that Wnt/β-catenin signaling plays a pivotal role
in regulating the miR-21 induction of stemness of colon cancer cells [9].
Although down-regulation of miR-21 is found to be associated with
a reduction in β-catenin levels in CR colon cancer cells [9], it is not
known whether down-regulation of either miR-21 or β-catenin would
also lead to attenuation of transcriptional activity of TCF/LEF. Our
results demonstrate that down-regulation of either miR-21 by anti–
miR-21 or β-catenin by the corresponding siRNA in CR colon cancer
HCT-116 or HT-29 cells caused a 50% to 60% reduction in transcrip-
tional activity of TCF/LEF (Figure 3A), accompanied by a significant
reduction in CD44 expression (Figure 3B) and a marked increase in
CK20 expression (Figure 3, B and C ), suggesting induction of differen-
tiation. Taken together, the results suggest a role for Wnt/β-catenin sig-
naling pathway in regulating miR-21–mediated differentiation of CR
colon cancer cells.
Down-regulation of miR-21 Increases the Cell Responsiveness
to Conventional and Nonconventional Therapeutics
CR colon cancer cells that are highly enriched in CSCs/CSLCs are
also poorly differentiated. To further determine whether induction of
differentiation would increase susceptibility to different therapeutics,
CR HCT-116 cells transfected with either the scrambled anti-miR
(controls) or anti–miR-21 were subsequently incubated for 48 hours
with FUOX (100 μM 5-FU + 2.5 μM oxaliplatin), CDF (2.0 μM),
Figure 2. Down-regulation of miR-21 in CR HCT-116 cells by anti–miR-21 (A) decreases the ability of cells to form spheroids as shown by the
representative photographs (magnification, ×10) taken after 7 days of transfection with either anti–miR-21 or scrambled miRNA (control),
(B) the number of spheres formed 7 days following transfection of anti–miR-21 or scrambledmiRNA; nontransfected CR-HCT-116 cells were
used as controls. Values are means ± SD. P < . 05, compared with scramble or untreated controls. (C) qRT-PCR (upper panel) showing
up-regulation of CK-20 mRNA in CR HCT-116 cells 48 hours following transfection of anti–miR-21, when compared with corresponding
scramble control (*P< .001). Western blot (lower panel) showing increased expression of CK-20 in CR HCT-116 cells following transfection
of anti–miR-21 when compared with the corresponding control cells; β-actin was used as a loading control. (D) Induction of alkaline phos-
phatase activity in CR HCT-116 cells 48 hours following transfection of anti–miR-21 (n = 3). Values are means ± SD. *P < .05, compared
with scramble transfected control.
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or the combination of CDF + FUOX. Indeed, we observed that in-
duction of differentiation of CR colon cancer cells increased their
sensitivity to the growth inhibitory properties of all three regimens
tested. However, the magnitude of inhibition of growth by either
CDF (75%) or CDF + FUOX (80%) was much higher than that
observed with FUOX alone (40%), suggesting that CDF and the
combination of CDF and FUOX are more effective than FUOX
in inhibiting the growth of differentiating CR colon cancer cells
(Figure 4A). This inference is further supported by the observation
that CDF and the combination of CDF and FUOX produced an
incredible 98% to 99% reduction in the expression of CD44 and
EGFR in the differentiating CR HCT-116 cells (Figure 4B). In con-
trast, FUOX by itself caused only a 60% reduction in CD44 and
EGFR expression (Figure 4B). Our current observation that CDF
and CDF + FUOX were highly effective in inhibiting growth and
reducing the expression of CD44 and EGFR in anti–miR-21–
induced differentiating CR HCT-116 cells supports our contention
that differentiating cells become susceptible to conventional as well
as nonconventional therapeutic regimens.
Down-regulation of CK-20 in CR Colon Cancer Cells
Causes No Apparent Change in Proliferation
Although knocking down miR-21 or β-catenin induces differentia-
tion, as evidenced by marked increases in CK-20 expression and alka-
line phosphatase activity and also increases susceptibility of CR colon
cancer cells to therapeutics, it is unclear if these changes are causally
related to growth inhibition or epiphenomena of loss of CSC/CSLC
characteristics that accompany down-regulation of miR-21. To address
this issue, we downregulated CK-20 in CR HT-29 cells using the
corresponding siRNA. The controls were transfected with scrambled
siRNA. Following transfection, the cells were incubated in the absence
or presence of FUOX for 48 hours. Transfection of CK-20–siRNA
in CR HT-29 cells produced a marked reduction in CK-20 expres-
sion (Figure 5, A and B). The protein and mRNA levels of CK-20
were substantially reduced (70–95% reduction), as determined by
qRT-PCR and Western blot analyses, when compared with the cor-
responding controls (Figure 5, A and B). However, down-regulation of
CK-20 in CR HT-29 cells produced no significant change in cellular
growth in the absence or presence of FUOX, when compared with
the corresponding controls (Figure 5C). In contrast, down-regulation
of miR-21 by antisense miR-21 that resulted in up-regulation of
CK-20 significantly decreased cellular growth in the absence (basal)
or presence of FUOX (Figure 5C ). The results suggest that CK-20
acts as a marker of differentiation and does not play any pivotal role
in regulating the growth of CR colon cancer cells.
Discussion
Although chemotherapeutic regimens consisting of 5-FU and other
anticancer drugs, such as FOLFIRI or FOLFOX, are used as a first
line of standard chemotherapy for patients with advanced colorectal
cancer, virtually all the responses are incomplete and emergence of
resistance, with subsequent recurrence of the cancer, is universal. Cur-
rently, effectiveness of conventional cancer therapeutics is usually eval-
uated by the reduction in tumor mass, resulting from elimination/
Figure 3. Down-regulation of either miR-21 or β-catenin in CR colon cancer cells (HCT-116 or HT-29) leads to attenuation of transcriptional
activation of TCF/LEF. (A) Relative transcriptional activities of TCF/LEF in CR colon cancer HCT-116 cells after down-regulation of either
miR-21 by anti–miR-21 or β-catenin by the corresponding siRNA, when compared with the corresponding controls that were similarly
treated with scramble miRNA or siRNA. *P < .001, compared with the corresponding scramble controls. (B and C) qRT-PCR showing
down-regulation of β-catenin in CR colon cancer HT-29 or HCT-116 cells by the corresponding siRNA leads to reduction in CD44 expression
and increase in CK20 expression in CR colon cancer HT-29 cells (B) and HCT-116 cells (C), compared with the corresponding controls. The
data represent means ± SD of three independent experiments, *P < .001.
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killing of differentiated or undifferentiated cells that form the bulk of
the tumor. However, the population of CSCs/CSLCs remains
untouched and may even be enriched resulting in relapse of the dis-
ease. Earlier, we reported that exposure of colon cancer HCT-116 or
HT-29 cells to FOLFOX that inhibited their growth led to enrich-
ment of CSC/CSLC phenotype as evidenced by significantly increased
proportion of CD44-, CD166-, and/or CD133-positive cells [8]
accompanied by increased colonosphere forming ability in vitro and
tumor formation in SCID mice [9].
It has been well documented that dysregulation of Wnt/β-catenin
signaling plays a pivotal role in the regulation of colonic stem cells,
which has also been implicated in colon carcinogenesis [25]. Our
earlier studies have also shown that Wnt/β-catenin signaling path-
way plays a pivotal role in regulating growth and maintenance of
CSC/CSLC-enriched colonies derived from various human colon
cancer cells such as colonospheres [20]. The colonospheres are found
to express LGR5, CD44, CD166, Musashi-1, and epithelial-specific
antigen, which are markers of CSCs/CSLCs, and show elevated levels
of total β-catenin causing exaggerated transcriptional activation of
TCF/LEF gene responsible for the progression of cancer stem cells
[20]. Colon cancer HCT-116 cells are heterozygous for β-catenin,
harboring one wild-type allele and one mutant allele with inactivation
of SER45, one of the residues phosphorylated by GSK3β [24,26].
Since one of alleles is wild type, we believe that this might be respon-
sible for siRNA-induced down-regulation of β-catenin.
More interestingly, our studies also show that miR-21, whose levels
are greatly increased in colon tumors, is also greatly elevated in CR
colon cancer cells [9]. Overexpression of miR-21 led to increased
TCF/LEF activity, increased sphere forming ability in vitro, and tumor
formation in SCID mice and that down-regulation of miR-21 in CR
colon cancer cells markedly decreased their sphere-forming ability, a
phenomenon similar to that noted for β-catenin downregulated cells,
Figure 4. Down-regulation of miR-21 increases the CR colon cancer
cell susceptibility to conventional therapeutic FUOX, nonconven-
tional therapeutic CDF, and the combination of FUOX plus CDF.
(A) MTT assay showing growth inhibition of anti–miR-21 or scramble
miRNA-transfected CR HCT-116 cells in response to FUOX (100 μM
5-FU + 2.5 μM oxaliplatin), CDF (2.0 μM), or the combination of
CDF+FUOXcompared to the untreated cells (control). The cellswere
exposed to the therapeutic agents for 48 hours. Each value repre-
sents mean ± SD of six observations; *P< .001. (B) qRT-PCR show-
ing anti–miR-21–transfected CR HCT-116 cells; expression of CD44
and EGFR is greatly inhibited in response to FUOX, CDF, or CDF +
FUOX. Scramble miRNA-transfected CR cells were used as control;
*P < .001. The CR cells were maintained in FUOX (50 μM 5-FU +
1.25 μM oxaliplatin) throughout as stated above in Materials and
Methods section.
Figure 5. Down-regulation of CK-20 in CR colon cancer HT-29 cells causes no apparent change in proliferation and susceptibility
to FUOX. (A) Real-time qRT-PCR showing down-regulation of CK-20 48 hours following transfection with CK-20 siRNA. Data represent
means ± SD of three independent experiments; *P < .001, compared to the control. (B) Western blot analysis of CK-20 following down-
regulation of CK-20. (C)MTT assay showing the CRHT-29 cell proliferation and its susceptibility to FUOX after transfectionwith CK-20 siRNA,
anti–miR-21, and the scramble transfected (control). Data represent means ± SD of three independent experiments.
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supporting the contention that miR-21 regulates some of the func-
tional properties of colon CSCs [9].
These observations prompted us to examine whether down-regulation
of miR-21 in CR colon cancer cells would induce differentiation of
CSCs/CSLCs and render them susceptible to the conventional or
nonconventional chemotherapeutic regimens. The basis for this inves-
tigation is that while CSCs/CSLCs are resistant to conventional chemo-
therapy, differentiated or differentiating cells that form the bulk of the
tumor are sensitive to chemotherapy. In the current investigation, we
have observed that down-regulation of miR-21 in CR HCT-116 cells,
which are highly enriched in CSCs/CSLCs, leads to differentiation as
evidenced by increased expression of gastrointestinal differentiation
marker CK-20 [23] and an increase in alkaline phosphatase activity
[27,28] and may also be causally related to decreased levels of CD44,
pri-miR-21, and EGFR.
We have also hypothesized that down-regulation of miR-21 in
CR cells that leads to differentiation would render them susceptible
to conventional or nonconventional chemotherapeutics. CDF, a newly
developed analog of curcumin with a greater bioavailability than the
parent compound, have been shown to exert a greater growth inhibi-
tory property than curcumin [7]. Recent studies also showed that CDF
was much more superior in the killing of gemcitabine-resistant pan-
creatic cancer cells with epithelial-to-mesenchymal phenotype that is
reminiscent of CSCs [29]. We have reported that CDF in combination
with FUOX causes growth inhibition in CR colon cancer cells in vitro,
decreases the proportion of CSCs/CSLCs, and inhibits expression of
miR-21 [7]. Our current observation that following down-regulation
of miR-21 in CR colon cancer HCT-116 cells they become highly
susceptible to the growth inhibitory properties of FUOX, CDF, and
CDF + FUOX clearly indicate increased vulnerability of CSC/CSLC-
enriched CR colon cancer cells not only to conventional therapeutic
FUOX but also to nonconventional therapeutics such as CDF or the
combination of FUOX and CDF. Furthermore, the fact that down-
regulation of CK-20 by the corresponding siRNA produced no sig-
nificant change in cellular growth of CR colon cancer cells in the
absence or presence of FUOX suggest that CK-20 per se is not involved
in regulating the growth of CR colon cancer cells but acts as a marker
of differentiation.
In conclusion, the results of our current investigation suggest that
down-regulation of miR-21 is an effective therapeutic strategy for CR
colon cancer by regulating cancer stem cell differentiation and sub-
sequently rendering them susceptible to therapeutic agents.
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